ArticleJournal of managed care & specialty pharmacy2020
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.
Article in Journal of managed care & specialty pharmacy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.PharmacoEconomics · 2021Pooled it
- Patient-Centered Value Elements in the Economic Evaluation of Chronic Obstructive Pulmonary Disease (COPD): A Targeted Review of Cost-Effectiveness Analyses.PharmacoEconomics · 2026Review
- A Cost-Effectiveness Analysis for Treatments of Patients with Early Stage Huntington's Disease in the USA.PharmacoEconomics - open · 2026Article
- Introducing an Expanded Value Framework in Health Technology Assessment of Vaccines.Journal of market access & health policy · 2026Article
- Reflecting Social Values in HTA Methods: A Case Study of South Africa.Applied health economics and health policy · 2025Review
- Defining the value proposition in diagnostic technology: challenges and opportunities for its understanding and development - a review with a multiperspective reflective analysis.Frontiers in medicine · 2025Review
- Val (EU) xit: do we need an international ISPOR value flower?Journal of comparative effectiveness research · 2024Article
- Incorporating Real Option Value in Valuing Innovation: A Way Forward.PharmacoEconomics · 2024Article
- Health Equity Considerations in Cost-Effectiveness Analysis: Insights from an Umbrella Review.ClinicoEconomics and outcomes research : CEOR · 2024Review
- A review of HTA guidelines on societal and novel value elements.International journal of technology assessment in health care · 2023Review
- Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods.PharmacoEconomics - open · 2023Article
- Reconstructing the value puzzle in health technology assessment: a pragmatic review to determine which modelling methods can account for additional value elements.Frontiers in pharmacology · 2023Review
- Assessing potential cures: are there distinctive elements of value beyond health gain?Journal of comparative effectiveness research · 2021Article
- Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?Cost effectiveness and resource allocation : C/E · 2021Article
- What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society?PharmacoEconomics · 2020Article
- Health technology assessment with risk aversion in health.Journal of health economics · 2020Article
- Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability.Journal of managed care & specialty pharmacy · 2020Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
disclosuresThis study received unrestricted funding from the Pharmaceutical Research Manufacturers of America. The authors also do consulting, personally or through their employment, with numerous pharmaceutical manufacturers, payers, and other stakeholders with a general interest in this subject matter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.